TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11132749
Drug: Nicardipine 0.017
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 0.017 mg x kg(‐1) administered as a bolus
Study: 8406060
Drug: Nicotine (2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (2-4 mg in gum base)
Study: 3778815
Drug: Behavioural method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural method of habit reversal combined with hydrocortisone cream
Study: 3778815
Drug: Regular ointment
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular ointment treatment (hydrocortisone cream alone)
Study: 30081859
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg per night of capsulated sustained-release melatonin (Circadin)
Study: 30081859
Drug: 1 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo capsule
Study: 27274009
Drug: Pradigastat (115
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradigastat (115 mg intravenously)
Study: 27274009
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg oral, positive control)
Study: 25738335
Drug: Conical interface
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conical interface (CI; OsseoSpeed, Dentsply Implants), n = 4
Study: 21840915
Drug: telephone cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: telephone cognitive behavioural therapy emphasizing physical activity
Study: 19842352
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment consisting of stretching, posture training, and auricular acupuncture
Study: 15231974
Drug: Early-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-treatment group (M&T performed promptly)
Study: 15231974
Drug: Late-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late-treatment group (M&T performed after a defined extended period)
Study: 11409520
Drug: 5000 U
Normalized name: lipase 5000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 U of heparin
Study: 8591483
Drug: Improved access
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved access to medication
Study: 2475710
Drug: Isradipine (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5, 5, and 7.5 mg b.i.d. every 3rd week)
Study: 31148210
Drug: Enteral dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral dextrose infusion for 24 hours (n=30)
Study: 31148210
Drug: Water (placebo)
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (placebo) infusion for 24 hours (n=30)
Study: 25906706
Drug: NCH gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCH gel
Study: 24742116
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioural therapy (CBT)
Study: 22948406
Drug: TeleFamilies intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TeleFamilies intervention with advanced practice nurse as care coordinator; details on dosage and duration not specified.
Study: 16200556
Drug: Hospital chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital chemotherapy
Study: 15785179
Drug: Endovascular therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapies (angioplasty, stenting, endoluminal stent grafts)
Study: 8497821
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate with a 750 ml spacer (group S)
Study: 8497821
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups at 2 mg/day of beclomethasone dipropionate
Study: 20810877
Drug: Aphasia treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aphasia treatment targeting anomia (30 hours of treatment)
Study: 20810877
Drug: Aphasia treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aphasia treatment targeting anomia
Study: 18438689
Drug: Topical morphine
Normalized name: morphine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical morphine (0.1%, 0.2%, 0.4%)
Study: 18438689
Drug: Topical buprenorphine
Normalized name: buprenorphine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical buprenorphine (0.01%, 0.02%, 0.1%)
Study: 15958804
Drug: Bortezomib (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.3 mg/m² IV on days 1, 4, 8, and 11 for eight three-week cycles, then days 1, 8, 15, and 22 for three five-week cycles)
Study: 15958804
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (40 mg orally on days 1-4, 9-12, and 17-20 for four five-week cycles, then days 1-4 for five four-week cycles)
Study: 10643226
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with insulin and metformin
Study: 8896734
Drug: Cyclosporine and
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine and steroid immunosuppressive therapy (CSA regimen)
Study: 8896734
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cyclosporine (4 mg/kg/day), steroid therapy, and 21-day course of 500 mg/day antilymphocyte globulin (ALG 1 regimen)
Study: 8896734
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cyclosporine (6 mg/kg/day), steroid therapy, and 14-day course of 1,000 mg/day antilymphocyte globulin (ALG 2 regimen)
Study: 8896734
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cyclosporine (6 mg/kg/day), steroid therapy, and 14-day course of 1,000 mg/day antilymphocyte globulin followed by 2 mg/kg/day mizoribine (ALG 3 regimen)
Study: 8896734
Drug: FK506 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK506 and steroid therapy (FK506 regimen)
Study: 8896734
Drug: Cyclosporine and
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine and steroid therapy
Study: 24553695
Drug: Echium oil
Normalized name: Echium plantagineum seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echium oil (EO) 17 g/d (2 g SDA)
Study: 24553695
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) 17 g/d (1.9 g EPA)
Study: 23249501
Drug: Adjunctive rifampicin
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive rifampicin (600-900 mg/day; orally or intravenously)
Study: 20456738
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg daily
Study: 18215589
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) with drug-eluting stents (DESs)
Study: 16199841
Drug: Community-delivered psychodynamic
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-delivered psychodynamic therapy
Study: 14520722
Drug: 25‐OH‐vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25‐OH‐vitamin D (cholecalciferol) 15 microg (600 IU) once daily
Study: 11220352
Drug: Acarbose (half
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (half a pill before lunch and half a pill before dinner)
Study: 1856305
Drug: Chlorhexidine gel
Normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gel 2%
Study: 1856305
Drug: Amine fluoride
Normalized name: triethylene amine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amine fluoride gel 1.25%
Study: 1856305
Drug: Stannous fluoride
Normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stannous fluoride gel 4%
Study: 7174305
Drug: Pizotifen 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pizotifen 0.5 mg t.d.s.
Study: 7174305
Drug: Pizotifen 1.5
Normalized name: Pizotifen 1.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pizotifen 1.5 mg nocte
Study: 31214178
Drug: Tadalafil and
Normalized name: finasteride and tadalafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil and MUC1/polyICLC vaccine
Study: 2499203
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg praziquantel
Study: 28174906
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg praziquantel
Study: 28174906
Drug: 3 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 × 25 mg/kg praziquantel
Study: 15116254
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin (LMWH) thromboprophylaxis
Study: 11668032
Drug: Neostigmine (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.25, 0.75, or 1.5 mg)
Study: 11668032
Drug: Bethanechol (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bethanechol (2.5, 5, or 10 mg)
Study: 28763881
Drug: Memantine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine combined Reinhartdt And Sea Cucumber Capsule (R.S.C)
Study: 25619686
Drug: Aloe cream
Normalized name: VIT A/VIT E/ALOE CREAM
DrugBank: Aloe ferox leaf (DB14257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe cream
Study: 18840368
Drug: Midodrine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (5 mg, oral)
Study: 12580653
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of HMB per day for 4 weeks
Study: 10831205
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (1.0 mg for age > 60 yr; 1.5 mg for age ≤ 59 yr)
Study: 2428219
Drug: Tiacrilast (Ro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiacrilast (Ro 22-3747) 350 mg oral dose
Study: 2428219
Drug: Cromoglycate 20
Normalized name: cromoglycate
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromoglycate 20 mg by inhalation
Study: 27861516
Drug: mCME intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mCME intervention - Group 2 (passive model): daily SMS bullet point, required to reply to acknowledge receipt
Study: 24508367
Drug: short-term psychotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: short-term psychotherapy (short-term psychodynamic or solution-focused)
Study: 18591525
Drug: Sucrose (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (2 mL of a 24% sucrose solution)
Study: 12939564
Drug: nifedipine gastrointestinal
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nifedipine gastrointestinal therapeutic system 30 mg
Study: 8869092
Drug: Cisplatin 6
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 6 mg/m2 administered 1-2 hours before each radiation fraction, with escalating total doses during treatment.
Study: 6238116
Drug: ICI 118630
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118630 (Zoladex) 3.6 mg
Study: 6238116
Drug: ICI 118630
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118630 (Zoladex) 1.8 mg
Study: 6238116
Drug: ICI 118630
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118630 (Zoladex) 0.9 mg
Study: 6238116
Drug: ICI 118630
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118630 (Zoladex) (all doses)
Study: 25339485
Drug: Spironolactone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (20 mg/d) treatment group
Study: 22866821
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus dipyridamole (A + D)
Study: 22866821
Drug: Aspirin only
Normalized name: Aspirin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin only (A)
Study: 19931382
Drug: 2+1-dose schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2+1-dose schedule
Study: 19931382
Drug: 3+1-dose schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3+1-dose schedule
Study: 15705360
Drug: Riluzole (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (50-200 mg/day)
Study: 15705360
Drug: Lithium (open
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (open treatment for a minimum of 4 weeks)
Study: 11917239
Drug: Cyclosporin-A (CsA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin-A (CsA) 2 mg/kg twice daily for 12 weeks
Study: 9457004
Drug: Self-administered physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered physical activity frequency questionnaire (PAFQ)
Study: 2220725
Drug: Sucralfate suspension
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate suspension (1 g/10 ml) plus cimetidine (300 mg qid)
Study: 31633789
Drug: Lower-dose venlafaxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose venlafaxine (≤150 mg/d)
Study: 25707477
Drug: NNC0109‐0012 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0109‐0012 (3 mg/kg per week, subcutaneously)
Study: 23388003
Drug: Rivaroxaban, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban, 10 mg once daily for 35±4 days
Study: 23388003
Drug: Enoxaparin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin, 40 mg once daily for 10±4 days followed by placebo
Study: 21163281
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 3 mg kg(‐1) ingested 60 min before and 45 min after exercise in 33°C
Study: 19474135
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g low-TFA lipids/d (0.54 g/d; n = 21)
Study: 19474135
Drug: Ruminant TFA-rich
Normalized name: Maltose-rich malted barley extract
DrugBank: Barley malt syrup (DB14601)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruminant TFA-rich lipids (4.86 g/d; n = 21)
Study: 19474135
Drug: Industrial TFA-rich
Normalized name: Maltose-rich malted barley extract
DrugBank: Barley malt syrup (DB14601)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Industrial TFA-rich lipids (5.58 g/d; n = 21)
Study: 15209643
Drug: Galantamine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine at a maintenance dose of 16 or 24 mg/d
Study: 11575284
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of ADL 8‐2698
Study: 11575284
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of ADL 8‐2698
Study: 9783800
Drug: Thiotepa (TTP)
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Thiotepa (TTP) 5 mg/kg x 2 days (days -4, -3) along with busulfan (BU) 4 mg/kg x 4 days and cyclophosphamide (CY) 60 mg/kg x 2 days
Study: 7868872
Drug: Parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parathyroid hormone levels
Study: 2908008
Drug: Urapidil 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil 15 mg intravenously
Study: 2908008
Drug: Urapidil 30
Normalized name: urapidil 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil 30 mg intravenously
Study: 2908008
Drug: Urapidil (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (both doses)
Study: 31704549
Drug: Vemurafenib 960
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib 960 mg twice daily for 52 weeks
Study: 28566525
Drug: RRR-alpha-tocopherol (40.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRR-alpha-tocopherol (40.2 mg)
Study: 28566525
Drug: MIX (22.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIX (22.8 mg all-rac-alpha-tocopherol acetate + 20.1 mg RRR-alpha-tocopherol)
Study: 28566525
Drug: ARAC (45.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARAC (45.5 mg all-rac-alpha-tocopherol acetate)
Study: 24750558
Drug: Tapentadol PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol PR 300 mg/day
Study: 24750558
Drug: Tapentadol PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol PR 500 mg/day
Study: 24750558
Drug: Tapentadol PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol PR 300 mg/day plus pregabalin 300 mg/day
Study: 9562314
Drug: Collar therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collar therapy for 6 weeks
Study: 9562314
Drug: Collar therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collar therapy for 12 weeks
Study: 9562314
Drug: Collar therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collar therapy
Study: 8179463
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral treatment (CBT) including breathing retraining, muscle relaxation, cognitive reframing, and exposure to interoceptive and agoraphobic stimuli for 12 sessions.
Study: 8179463
Drug: Nonprescriptive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonprescriptive treatment (reflective listening) for 12 sessions.
Study: 2888638
Drug: Ranitidine 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 250 mg hs for four days prior to chloroquine administration
Study: 2888638
Drug: Chloroquine sulfate
Normalized name: Chloroquine sulfate
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine sulfate (300‐mg base) only
Study: 29630101
Drug: CT-guided implantation
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-guided implantation of 125I seeds in combination with chemotherapy
Study: 27158849
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for adherence and depression (CBT‐AD)
Study: 24047799
Drug: Rotarix™ vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotarix™ vaccine
Study: 19861187
Drug: Aerosolized Triviraten
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized Triviraten vaccine (including Rubini mumps strain)
Study: 19861187
Drug: Aerosolized Edmonston-Zagreb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized Edmonston-Zagreb (EZ) measles vaccine
Study: 19861187
Drug: Injected Moraten
Normalized name: morantel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected Moraten measles vaccine (twice the dosage)
Study: 19861187
Drug: Aerosolized mumps
Normalized name: mumps virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized mumps vaccine (Leningrad-Zagreb strain)
Study: 9833911
Drug: Prednisone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (30 mg per day initially, tapered to 10 mg daily after 8 weeks) and azathioprine (50 mg daily)
Study: 7978715
Drug: Clarithromycin 1000
Normalized name: clarithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 1000 mg twice daily
Study: 7978715
Drug: Clarithromycin 2000
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 2000 mg twice daily
Study: 2688237
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (lidocaine/prilocaine)
Study: 999302
Drug: Fluorouracil and
Normalized name: Fluorouracil and salicylic acid only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil and 0.5% triamcinolone acetonide cream
Study: 999302
Drug: Diluted (0.1%)
Normalized name: phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diluted (0.1%) triamcinolone acetonide cream
Study: 31692152
Drug: Plasma CRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma CRP ≥2.0 mg/l
Study: 26059332
Drug: Selumetinib 75
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib 75 mg twice daily in combination with dacarbazine 1000 mg/m² on Day 1 of every 21-day cycle
Study: 26059332
Drug: Dacarbazine 1000
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine 1000 mg/m²
Study: 9832976
Drug: Levodopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (100 mg) and benserazide (25 mg)
Study: 8508870
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose intravenous antibiotic prophylaxis (4 g piperacillin and 800 mg tinidazole 30 minutes before surgery)
Study: 8508870
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose intravenous antibiotic prophylaxis (4 g piperacillin 30 minutes before surgery, 4 g piperacillin 8 hours after, and 4 g piperacillin and 800 mg tinidazole 16 hours after the first dose)
Study: 29436896
Drug: Routine health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine health education delivered monthly by community nurses (Control)
Study: 23345601
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day avocado-soybean unsaponifiable (ASU-E)
Study: 21568147
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (Group A): omeprazole, amoxicillin, metronidazole, and bismuth, twice daily for 2 weeks
Study: 21568147
Drug: Ciprofloxacin based
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin based triple therapy (Group C): omeprazole and amoxicillin, twice daily for 2 weeks, and ciprofloxacin twice a day for the first week
Study: 21568147
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (Group D): omeprazole, amoxicillin for 5 days, followed by omeprazole, clarithromycin, and metronidazole for the remaining 5 days, all twice daily for 10 days
Study: 21568147
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group B): omeprazole, amoxicillin, and clarithromycin, twice daily for 10 days